Myriad Genetics, Inc. (MYGN)

Market Cap	673.64M
Revenue (ttm)	832.90M
Net Income (ttm)	-395.20M
Shares Out	93.04M
EPS (ttm)	-4.33
PE Ratio	n/a
Forward PE	193.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000,477
Open	7.64
Previous Close	7.68
Day's Range	7.22 - 7.80
52-Week Range	3.76 - 29.30
Beta	1.93
Analysts	Hold
Price Target	13.50 (+86.46%)
Earnings Date	Nov 6, 2025

About MYGN

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and meta...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 5, 1995
• Employees: 2,700
• Stock Exchange: NASDAQ
• Ticker Symbol: MYGN
• Website: https://www.myriad.com

Financial Performance

In 2024, Myriad Genetics's revenue was $837.60 million, an increase of 11.21% compared to the previous year's $753.20 million. Losses were -$127.30 million, -51.65% less than in 2023.

Analyst Summary

According to 13 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price target is $13.5, which is an increase of 86.46% from the latest price.

Price Target

$13.5

(86.46% upside)

Analyst Consensus: Hold